alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Newest studies

Every summary in our library, newest first, as a dated timeline.

What "newest" means here

The most recent study in this library is dated 2026-11-01 (Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment). This is our summary library, not a news wire — it is added to in batches, so the newest entry may not be the newest paper published anywhere.

Entries are sorted strictly by publication date, newest first. 26489 of the 27380 entries carry a full day-level date. 65 have no date recorded at all and are placed by publication year, at the start of that year; those are marked "no date recorded" below so you can see where the ordering is a best effort rather than a fact.

Prefer a reader? Subscribe to the Atom feed. Want them sorted by subject or by score instead? Browse the research library.

Showing 2,401–2,425 of 27,380 studies, newest first · page 97 of 1096.

December 2025 25

  1. 2025-12-01

    Comparing Off‐Target Meningeal and Skull Signal in Head‐to‐Head MK‐6240 and AV‐1451 Tau PET

    ✓ Peer-reviewed Brain scans and imaging Alzheimer s & Dementia

    Key finding: Average age of participants was 66 (21-88) years. 25 were biologically female and 15 were amyloid positive. +4 more findings

    Full summary, score breakdown and related studies → Original source

  2. 2025-12-01

    External Validation of Joint Propagation Model‐Based Tau PET CenTauR units

    ✓ Peer-reviewed Brain scans and imaging Alzheimer s & Dementia

    Key finding: These analyses suggest that CenTauR harmonization increases the comparability of tau‐PET data acquired with different tracers. +1 more finding

    Full summary, score breakdown and related studies → Original source

  3. 2025-12-01

    (DIADEM) Digital Assessment of Auditory Perception in Dementia : Study Protocol

    ✓ Peer-reviewed Getting a diagnosis Alzheimer s & Dementia

    Key finding: We will assess the utility of auditory perceptual tests, both alone and combined with blood-based biomarkers (pTau217 and NfL), for diagnosis and prognosis in individuals with cognitive symptoms. +2 more findings

    Full summary, score breakdown and related studies → Original source

  4. 2025-12-01

    Comparison of the Montreal Cognitive Assessment and the Mini‐Mental State Examination in community‐dwelling very old Blacks/African Americans

    ✓ Peer-reviewed Getting a diagnosis Alzheimer s & Dementia

    Key finding: Participants had age mean = 81.7, SD = 4.5, range=75-93; educational attainment mean = 14.6, SD = 4.0, range=7-22, 17.2% < 12; 86.2% were women. +4 more findings

    Full summary, score breakdown and related studies → Original source

  5. 2025-12-01

    Correlation of the Severity of Dementia with EEG Findings

    ✓ Peer-reviewed Getting a diagnosis Acta Medica International

    Key finding: The mean age of the cohort was 77.4 ± 6.8 years, with 62% males and nearly equal urban–rural distribution. +4 more findings

    Full summary, score breakdown and related studies → Original source

  6. 2025-12-01

    Tablet‐based Cognitive Assessment Tool (TabCAT) in a multisite study of early‐onset Alzheimer's disease

    ✓ Peer-reviewed Getting a diagnosis Alzheimer s & Dementia

    Key finding: TabCAT tests showed good convergent validity with traditional pen-and-paper tests. +4 more findings

    Full summary, score breakdown and related studies → Original source

  7. 2025-12-01

    Multi-modal data analysis for early detection of alzheimer’s disease and related dementias

    ✓ Peer-reviewed Getting a diagnosis The Journal of Prevention of Alzheimer s Disease

    Key finding: Until recently, accurate early detection of clinical symptoms associated with Alzheimer's disease (AD) and related dementias (ADRD) has been difficult. +1 more finding

    Full summary, score breakdown and related studies → Original source

  8. 2025-12-01

    Diagnostic Accuracy of FDG‐PET‐CT in Dementia: Assessing False Negatives in Clinical Practice

    ✓ Peer-reviewed Getting a diagnosis Alzheimer s & Dementia

    Key finding: The proportion of false negatives from FDG-PET ranged from 11-55%. +4 more findings

    Full summary, score breakdown and related studies → Original source

  9. 2025-12-01

    Cognitive Assessment of Dementia Patients Using Large Language Models

    ✓ Peer-reviewed Getting a diagnosis Alzheimer s & Dementia

    Key finding: The study included 685 patients who underwent MDS-cognitive and 3,630 patients assessed using OASIS. +4 more findings

    Full summary, score breakdown and related studies → Original source

  10. 2025-12-01

    Acceptable standards for clinic‐based digital cognitive assessments: Recommendations from the Global CEO Initiative on Alzheimer's Disease

    ✓ Peer-reviewed Getting a diagnosis Alzheimer s & Dementia

    Key finding: Digital cognitive assessments (DCAs) offer a promising solution by addressing longstanding barriers to routine cognitive testing and diagnosis. +4 more findings

    Full summary, score breakdown and related studies → Original source

  11. 2025-12-01

    Parkinson's Disease: The Epidemiology, Risk Factors, Molecular Pathogenesis, Prevention, and Therapy

    ✓ Peer-reviewed Prevention and risk MedComm

    Key finding: At the molecular level, we explore key disruptions including proteostatic failure, aberrant phase separation, oxidative stress, neuroinflammation, synaptic dysfunction, iron dyshomeostasis, and impaired cholesterol metabolism. +4 more findings

    Full summary, score breakdown and related studies → Original source

  12. 2025-12-01

    Vascular Considerations for Patients Receiving Amyloid Immunotherapy

    ✓ Peer-reviewed Treatments Innovation in Aging

    Key finding: Amyloid-related imaging abnormalities (ARIA) in the form of edema/effusions (ARIA-E) or hemorrhagic lesions (ARIA-H) are the most impactful adverse event associated with anti-amyloid immunotherapy for Alzheimer disease.

    Full summary, score breakdown and related studies → Original source

  13. 2025-12-01

    Imaging‐neuropathology evaluation of Amyloid Related Imaging Abnormality sulcal effusion in a DIAN‐TU‐001 participant treated with gantenerumab

    ✓ Peer-reviewed Treatments Alzheimer s & Dementia

    Key finding: Overall PiB-PET uptake increased during the first two years (before ARIA-E) and decreased during the last two years (including ARIA-E episodes) (0.03±0.05 vs. -0.04±0.04 SUVR/year, p-value=0.01, Figure 2). +4 more findings

    Full summary, score breakdown and related studies → Original source

  14. 2025-12-01

    Imaging‐neuropathology evaluation of Amyloid Related Imaging Abnormality sulcal effusion in a DIAN‐TU‐001 participant treated with gantenerumab

    ✓ Peer-reviewed Treatments Alzheimer s & Dementia

    Key finding: Overall PiB-PET uptake increased during the first two years (before ARIA-E) and decreased during the last two years (including ARIA-E episodes) (0.03±0.05 vs. -0.04±0.04 SUVR/year, p-value=0.01, Figure 2). +4 more findings

    Full summary, score breakdown and related studies → Original source

  15. 2025-12-01

    Neuropathological evaluation of the Boston Criteria v2.0 for cerebral amyloid angiopathy in Alzheimer's disease dementia

    ✓ Peer-reviewed Treatments Alzheimer s & Dementia

    Key finding: The Boston v2.0 criteria have low accuracy in patients with AD dementia.

    Full summary, score breakdown and related studies → Original source

  16. 2025-12-01

    Baseline Imaging Characteristics of Participants in the Phase II/III DIAN‐TU‐001 Tau NexGen Trial for Dominantly Inherited Alzheimer’s Disease

    ✓ Peer-reviewed Treatments Alzheimer s & Dementia

    Key finding: The study includes symptomatic DIAD participants and asymptomatic mutation carriers. +4 more findings

    Full summary, score breakdown and related studies → Original source

  17. 2025-12-01

    Leveraging digital twins for sample size reduction, powering secondary endpoints or subgroups in a simulated TRAILBLAZER‐ALZ 2 trial

    ✓ Peer-reviewed Treatments Alzheimer s & Dementia

    Key finding: Due to the reduced variability in endpoints when using digital twins as covariates in statistical analyses, the TRAILBLAZER-ALZ 2 trial could have enrolled up to 24% fewer control arm participants to draw the same conclusions about treatment efficacy as previously reported for the study's primary outcome, the integrated Alzheimer Disease Rating Scale (iADRS) at 18 months. +3 more findings

    Full summary, score breakdown and related studies → Original source

  18. 2025-12-01

    Model of the Impact of Pharmacological and Non-pharmacological Treatment of Alzheimer’s Disease

    ✓ Peer-reviewed Treatments [in]genio revista de investigación y labor creativa

    Key finding: El Alzheimer es un trastorno neurodegenerativo que afecta la cognición y memoria. +4 more findings

    Full summary, score breakdown and related studies → Original source

  19. 2025-12-01

    Rates of Alzheimer disease biomarker positivity stratified by by sex and race in a specialty memory clinic

    ✓ Peer-reviewed Treatments Alzheimer s & Dementia

    Key finding: The MDC used a combination of CSF tests, blood tests, and amyloid PET scans to scale up AD biomarker testing over the past three years.

    Full summary, score breakdown and related studies → Original source

  20. 2025-12-01

    Partial Mitochondrial Complex I Inhibitors as a Therapy for Alzheimer Disease

    ✓ Peer-reviewed Treatments Alzheimer s & Dementia

    Key finding: Like CP2, C458 and C273 weakly inhibit mtCI, leading to AMPK activation, which triggers a neuroprotective stress response. +4 more findings

    Full summary, score breakdown and related studies → Original source

  21. 2025-12-01

    Can Telehealth Improve Access to Amyloid-Targeting Therapies for Veterans Living With Alzheimer Disease?

    ✓ Peer-reviewed Treatments Federal Practitioner

    Key finding: The VHA is well-positioned to use a hybrid approach-both telehealth and in-person care-to support the provision of amyloid-targeting therapies for veterans with AD. +1 more finding

    Full summary, score breakdown and related studies → Original source

  22. 2025-12-01

    Parallel Paths, Uneven Progress: Health Care Provider and Patient Perspectives on Anti‐Amyloid Therapies for Early AD

    ✓ Peer-reviewed Treatments Alzheimer s & Dementia

    Key finding: As of April 3, 2025, 944 HCPs (neurologists 14%, geriatricians 5%, primary care providers 25%) and 2,269 P/Cs engaged with the contents. +4 more findings

    Full summary, score breakdown and related studies → Original source

  23. 2025-12-01

    Development of a novel anti‐amyloid therapeutic: an orally administrable anti‐abeta‐oligomer compound in early preventative intervention

    ✓ Peer-reviewed Treatments Alzheimer s & Dementia

    Key finding: Orally dosed D-AIP possessed favourable biostability, pharmacokinetics, and brain region distribution. +4 more findings

    Full summary, score breakdown and related studies → Original source

  24. 2025-12-01

    Mouse models for studying anti‐amyloid antibody‐induced ARIA

    ✓ Peer-reviewed Treatments Alzheimer s & Dementia

    Key finding: Thus far, studies of ARIA in amyloid mouse models have focused mainly on the development of microhemorrhages (ARIA-H) following chronic immunization. +4 more findings

    Full summary, score breakdown and related studies → Original source

  25. 2025-12-01

    Lecanemab bei Alzheimer-Krankheit: Frühe Therapie ist sicher

    ✓ Peer-reviewed Treatments Fortschritte der Neurologie · Psychiatrie

    Key finding: Wissenschaftler*innen der Washington Universität in St. +3 more findings

    Full summary, score breakdown and related studies → Original source

Browse the library by subject, with the full score breakdown →